Next Generation Sequencing

With over 400 DNA &1600 RNA NCCN Guideline supported genes, we offer hematologic and solid tumor molecular profiling as well as liquid biopsy testing, with results typically available in less than 10 days. Our panels include:

NGS Myeloid Profiles

Next generation sequencing (NGS) has proven to be particularly valuable in various hematologic malignancies including the diagnosis, prognosis and treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

CORE Myeloid Profile (MDS/MPN)

DNA expression useful in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid monocytic leukemia (CMML) and clonal hematopoiesis of indeterminate potential (CHIP).

CORE Acute Leukemia Expression-Fusion Profile (AML/ALL)

A comprehensive AML/ALL fusion profile evaluation for DNA/RNA that includes IDH1, IDH2, NPM and FLT3 among other genes.

CORE Liquid Biopsy

Liquid biopsy is a noninvasive alternative for monitoring therapy and early detection of relapse. With over 280 cell free DNA (cfDNA) & >1600 cell free fRNA (cfRNA) genes, a liquid biopsy sample can reliably detect:

Chromosomal abnormalities, including gene amplification
Fusions
Gene expression
Alternative splicing
HRR
HPV/EBV
Molecular Residual Disease (MRD)
Potential biomarkers through AI enhanced discovery, including those for immunotherapy

Our genomic profiling enables the detection and differentiation of driver and sub-clonal mutations, determines prognosis and identifies targeted therapies for personalized medicine.

CORE Solid Tumor Expression Profile

Comprehensive evaluation of over 400 DNA and 1600 RNA genes including microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair (HRR) mutations and homologous recombination deficiency (HRD).